4 More Key FDA Decisions in March
24/7 Wall St. has collected a few more U.S. Food and Drug Administration (FDA) decisions coming up in March.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 221
Why One Analyst Sees Gilead Worth 66% More
Argus reiterated Gilead Sciences as Buy, but hat really matters here is that Argus has a $150 price target on the stock.
Bio Blast Pharma Explodes on Positive Results
Bio Blast Pharma was blowing away all the other bulls in Wednesday’s session, with its stock up over 150% on positive clinical results.
Cerus Tumbles Despite FDA Approval
Shares of Cerus dropped just after the open of Wednesday’s regular trading session despite a key FDA approval.
Valeant CEO Michael Pearson Has to Leave
CEO Michael Pearson needs to leave Valeant Pharmaceuticals for it to have any chance to recover. The company cannot afford to keep him.
Celator Pharma Skyrockets on Breakthrough Trial Results
Celator Pharmaceuticals has announced positive results from its Phase 3 trial of Vyxeos Liposome for Injection in patients with high-risk (secondary) acute myeloid leukemia.
Aeglea BioTherapeutics Prepares for IPO
Aeglea BioTherapeutics has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Huge Opportunity, and Risks, in 5 Top Abuse-Deterrent ER Opioids
One analyst firm believes the development of abuse-deterrent formulations (ADF) of opioids creates a risk that older non-ADFs may be removed from the market, creating a huge risk and opportunity in the space.
Valeant Pharma Trips Over Preliminary Earnings and Guidance
Valeant Pharmaceuticals International reported mixed preliminary fourth-quarter financial results before the markets opened on Tuesday.
Jefferies Top Drug Stocks for the Rest of 2016
For the most part, Jefferies maintained its list of top companies in the health care sector, but it also made a couple additions and updated its price target information.
Vericel Trips Over Earnings
Vericel Corp. (NASDAQ: VCEL) reported its fourth-quarter financial results before the markets opened on Monday. The company said it had a net loss of $0.28 per share on $15.4 million in revenue, which compares…
Senseonics Gears Up for IPO
Senseonics Holdings has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were given in the filing for the 18.2 million shares with…
What to Expect From Valeant Pharma Q4 Earnings
Valeant Pharmaceuticals is scheduled to report its fourth-quarter preliminary results and update its 2016 financial guidance in a conference call Tuesday morning.
GW Pharma Explodes on Positive Late-Stage Results
GW Pharmaceuticals has announced the positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex for the treatment of Dravet syndrome.
5 Key FDA Decisions Expected in March
24/7 Wall St. has collected three big FDA decisions coming up in March and added some color, along with the trading range and price target.